FDA priority review advances Atara’s tabelecleucel for viral infection
Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.
Approval of tabelecleucel would mark the first available therapy for the treatment of EBV+PTLD in the US.
What's Your Reaction?
